Cranbury, New Jersey-based Palatin Technologies Inc.'s shares finished Friday's session 2.48% lower at $0.55. A total volume of 952,054 shares was traded. The stock has advanced 5.96% in the last month. The Company's shares are trading above their 200-day moving average by 3.01%. Moreover, shares of Palatin Technologies, which develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the US, have a Relative Strength Index (RSI) of 48.44.
On December 07th, 2016, Palatin Technologies announced that it has closed on a previously disclosed underwritten public offering of units with gross proceeds of $16,500,000. In the offering Palatin issued 25,384,616 shares of its common stock and five year Series J warrants to purchase 12,692,310 shares of its common stock at an exercise price of $0.80 per share. PTN complete research report is just a click away and free at: http://stock-callers.com/registration/?symbol=PTN
Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. ended the day 1.42% lower at $34.75. A total volume of 2.35 million shares was traded, which was above their three months average volume of 785,600 shares. The stock has advanced 11.20% in the last month, 40.18% over the previous three months, and 15.10% since the start of this year. The Company's shares are trading 19.17% and 38.04% above their 50-day and 200-day moving averages, respectively. Moreover, shares of AMAG Pharma, which provides products and services with a focus on maternal health, anemia management, and cancer supportive care in the US, have an RSI of 59.47.
On December 15th, 2016, AMAG Pharmaceuticals announced that the company has awarded $300,000 in grant - an increase of $150,000 from last year - to fund research aimed at reducing premature birth and improving the health of neonates and infants in the US through its Prematurity Research Grants Program. The 2016 grant recipients were selected by an independent external review panel of maternal fetal medicine specialists and an obstetrician. The panel was chaired by George Saade, M.D., Professor, Obstetrics/Gynecology and Cell Biology at The University of Texas Medical Branch. The complimentary report on AMAG can be downloaded at: http://stock-callers.com/registration/?symbol=AMAG
Nassau, The Bahamas headquartered Nymox Pharmaceutical Corp.'s stock closed the session flat at $3.00 with a total trading volume of 65,673 shares. The Company's shares are trading 3.82% above their 200-day moving average. Shares of the Company, which engages in the research and development of drugs for the aging population, have an RSI of 43.04.
On November 29th, 2016, Nymox Pharma announced that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received fexapotide as their initial treatment for BPH (prostate enlargement) had superior efficacy results as early as 10 days compared to control patients who received placebo or who had prior history of other BPH medical treatments. These new Phase 3 results indicate that fexapotide in these trials was highly efficacious for first-line treatment of BPH. These findings are from analysis of the Company's extensive US Phase 3 trials NX02-0017, NX02-0018, NX02-0020 and NX02-0022 including long-term follow-ups that were undertaken from 2009 to 2016. Sign up for your complimentary research report on NYMX at: http://stock-callers.com/registration/?symbol=NYMX
On Friday, shares in Westbrook, Maine headquartered IDEXX Laboratories Inc. finished the session 0.40% lower at $119.43. A total volume of 1.21 million shares was traded, which was above their three months average volume of 516,990 shares. The stock has gained 5.92% in the last month, 7.94% over the previous three months, and 63.78% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 5.46% and 21.24%, respectively. Furthermore, shares of IDEXX Laboratories, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide, have an RSI of 57.66.
On November 15th, 2016, IDEXX Laboratories announced that Michael J. Williams, Ph.D., Executive Vice President, is departing from the Company in February of next year and stepping down from his current role in November 2016. Dr. Williams has been Executive Vice President since 2012 and has been employed by the Company since 2003. Get free access to your research report on IDXX at: http://stock-callers.com/registration/?symbol=IDXX
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA